Prediagnostic circulating antibodies to JC and BK human polyomaviruses and risk of non-Hodgkin lymphoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 15, Issue 3, 2006, Pages 543-550

  Rollison, Dana E ^a,b   Engels, Eric A ^d   Halsey, Neal A ^b   Shah, Keerti V ^b   Viscidi, Raphael P ^b   Helzlsouer, Kathy J ^b,c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MERCY MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; VIRUS ANTIBODY;

ADULT; ANTIBODY TITER; ARTICLE; BK VIRUS; CANCER REGISTRY; CANCER RISK; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; JC VIRUS; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RISK ASSESSMENT; UNITED STATES; VIRUS INFECTION; VIRUS PARTICLE; VIRUS REACTIVATION;

ADULT; AGE DISTRIBUTION; ANTIBODIES, VIRAL; BK VIRUS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INCIDENCE; JC VIRUS; LOGISTIC MODELS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POLYOMAVIRUS INFECTIONS; PREDICTIVE VALUE OF TESTS; REFERENCE VALUES; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SEX DISTRIBUTION; TUMOR VIRUS INFECTIONS;

EID: 33645521913     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0728     Document Type: Article

References (34)

1. Cancer Facts and Figures 2005. Atlanta (Georgia): American Cancer Society; 2005.
2. Dal ML, Franceschi S. Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol 2003;4:110-9.
3. Mueller N, Mohar A, Evans A, et al. Epstein-Barr virus antibody patterns preceding the diagnosis of non-Hodgkin's lymphoma. Int J Cancer 1991;49:387-93.
4. Muller AM, Ihorst G, Mertelsmann R, et al. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005;84:1-12.
5. Carter JJ, Madeleine MM, Wipf GC, et al. Lack of serologic evidence for prevalent simian virus 40 infection in humans. J Natl Cancer Inst 2003;95:1522-30.
6. Rollison DE, Helzlsouer KJ, Alberg AJ, et al. Serum antibodies to JC virus, BK virus, simian virus 40, and the risk of incident adult astrocytic brain tumors. Cancer Epidemiol Biomarkers Prev 2003;12:460-3.
7. Shah K. Polyomaviruses. In: Fields B, Knipe D, Howley P, editors. Fields virology. Philadelphia: Lippincott-Raven; 1996. p. 2027-43.
8. Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003;71:115-23.
9. Hou J, Major EO. Progressive multifocal leukoencephalopathy: JC virus induced demyelination in the immune compromised host. J Neurovirol 2000;6 Suppl 2:598-100.
10. Chang H, Wang M, Tsai RT, et al. High incidence of JC viruria in JC-seropositive older individuals. J Neurovirol 2002;8:447-51.
11. Ling PD, Lednicky JA, Keitel WA, et al. The dynamics of herpesvirus and polyomavirus reactivation and shedding in healthy adults: a 14-month longitudinal study. J Infect Dis 2003;187:1571-80.
12. Shah KV, Daniel RW, Strickler HD, et al. Investigation of human urine for genomic sequences of the primate polyomaviruses simian virus 40, BK virus, and JC virus. J Infect Dis 1997;176:1618-21.
13. Shah K. Polyoma viruses (JC virus, BK virus, and simian virus 40) and human cancer. In: Goedert JJ, editor. Infectious causes of cancer: targets for intervention. Totowa (New Jersey): Humana Press, Inc.; 2001. p. 461-74.
14. Dorries K, Sbiera S, Drews K, et al. Association of human polyomavirus JC with peripheral blood of immunoimpaired and healthy individuals. J Neurovirol 2003;9 Suppl 1:81-7.
15. Monaco MC, Atwood WJ, Gravell M, et al. JC virus infection of hematopoietic progenitor cells, primary B lymphocytes, and tonsillar stromal cells: implications for viral latency. J Virol 1996;70:7004-12.
16. Lazutka JR, Neel JV, Major EO, et al. High titers of antibodies to two human polyomaviruses, JCV and BKV, correlate with increased frequency of chromosomal damage in human lymphocytes. Cancer Lett 1996;109:177-83.
17. Neel JV, Major EO, Awa AA, et al. Hypothesis: "Rogue cell"-type chromosomal damage in lymphocytes is associated with infection with the JC human polyoma virus and has implications for oncopenesis. Proc Natl Acad Sci U S A 1996;93:2690-5.
18. Hernandez-Losa J, Fedele CG, Pozo F, et al. Lack of association of polyomavirus and herpesvirus types 6 and 7 in human lymphomas. Cancer 2005;103:293-8.
19. Del Valle L, Enam S, Lara C, et al. Primary central nervous system lymphoma expressing the human neurotropic polyomavirus, JC virus, genome. J Virol 2004;78:3462-9.
20. MacKenzie J, Wilson KS, Perry J, et al. Association between simian virus 40 DNA and lymphoma in the United kingdom. J Natl Cancer Inst 2003;95:1001-3.
21. Shivapurkar N, Harada K, Reddy J, et al. Presence of simian virus 40 DNA sequences in human lymphomas. Lancet 2002;359:851-2.
22. Vilchez RA, Madden CR, Kozinetz CA, et al. Association between simian virus 40 and non-Hodgkin lymphoma. Lancet 2002;359:817-23.
23. Engels EA, Rollison DE, Hartge P, et al. Antibodies to JC and BK viruses among persons with non-Hodgkin lymphoma. Int J Cancer 2005;117:1013-9.
24. Rollison DE, Helzlsouer KJ, Halsey NA, et al. Markers of past infection with simian virus 40 (SV40) and risk of incident non-Hodgkin lymphoma in a Maryland cohort. Cancer Epidemiol Biomarkers Prev 2005;14:1448-52.
25. Bush DM. The interaction of serum micronutrients with potential risk factors for the development of non-Hodgkin's lymphoma. Baltimore (Maryland): Dissertation thesis, The Johns Hopkins University School of Hygiene and Public Health; 1995.
26. Lenz P, Day PM, Pang YY, et al. Papillomavirus-like particles induce acute activation of dendritic cells. J Immunol 2001;166:5346-55.
27. Viscidi RF, Rollison DE, Viscidi E, et al. Serological cross-reactivities between antibodies to simian virus 40, BK virus, and JC virus assessed by virus-like-particle-based enzyme immunoassays. Clin Diagn Lab Immunol 2003;10:278-85.
28. Viscidi RP, hdieh-Grant L, Clayman B, et al. Serum immunoglobulin G response to human papillomavirus type 16 virus-like particles in human immunodeficiency virus (HIV)-positive and risk-matched HIV-negative women. J Infect Dis 2003;187:194-205.
29. Rothman N, Cantor KP, Blair A, et al. A nested case-control study of non-Hodgkin lymphoma and serum organochlorine residues. Lancet 1997;350:240-4.
30. Wei, Lin, Weissfeld. Regression analysis of multivariate incomplete failure time data by modeling marginal distributions. J Am Stat Assoc 1989;84:1065-78.
31. Khalili K, Del VL, Otte J, et al. Human neurotropic polyomavirus, JCV, and its role in carcinogenesis. Oncogene 2003;22:5181-91.
32. Atwood WJ, Amemiya K, Traub R, et al. Interaction of the human polyomavirus, JCV, with human B-lymphocytes. Virology 1992;190:716-23.
33. Vineis P, Miligi L, Crosignani P, et al. Delayed infection, family size and malignant lymphomas. J Epidemiol Community Health 2000;54:907-11.
34. Grulich AE, Vajdic CM, Kaldor JM, et al. Birth order, atopy, and risk of non-Hodgkin lymphoma. J Natl Cancer Inst 2005;97:587-94.